

Tesamorelin + Ipamorelin Dosing Chart

A pairing of the approved GHRH analog tesamorelin with the secretagogue ipamorelin. Tesamorelin alone is approved; the combination is not studied. Commonly discussed doses: 1 mg–2 mg. No established dosing exists for the combination. Figures reflect the tesamorelin component's labeled amount. Ipamorelin is unapproved and unstandardized in blends.

thelastpeptide.com · Medically reviewed by Charles Maddix, MSN, APRN, PMHNP-BC · Last reviewed 2026-08-02

FDA STATUS

Tesamorelin is FDA-approved as Egrifta for HIV-associated lipodystrophy. Ipamorelin is not approved, and no combination of the two is approved or studied.

5 mg vial — units to draw (U-100 syringe)

Water added	mg/mL	1 mg	2 mg
1 mL	5	20 u	40 u
2 mL	2.5	40 u	80 u
3 mL	1.67	60 u	—

10 mg vial — units to draw (U-100 syringe)

Water added	mg/mL	1 mg	2 mg
1 mL	10	10 u	20 u
2 mL	5	20 u	40 u
3 mL	3.33	30 u	60 u

"—" means the draw exceeds one syringe at that concentration. Interactive calculator for any combination: thelastpeptide.com/peptides/tesamorelin-plus-ipamorelin

Tesamorelin + Ipamorelin dose figures are commonly discussed reference information with no approved labeling unless stated above. The Last Peptide is an educational reference and sells nothing. Dosing figures shown here are commonly discussed reference information, not prescriptions or medical advice. Many peptides listed are not FDA-approved. Talk to a licensed clinician before using any peptide.